07/11/2017
ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA
Orphazyme A/S ("Orphazyme" or the "Company"), a Danish biotech company with a late stage orphan drug pipeline, today announced that the U.S. Food and Drug Administration (“FDA”), Office of Orphan Products Development, has granted an orphan drug designation to [...]
